Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Demirci, Nebi; AKSOY, SERCAN; ÖZDEMİR, NURİYE; Erdem, Gokmen; Ozcelik, Melike; Tanrikulu, Eda; Eren, Tulay; Bozkaya, Yakup; Sahin, Suleyman; Basol, Fatma; Aslan, Suheyla; Zengin, Nurullah; Gullu, Ibrahim

doi:10.1080/03007995.2016.1257984

Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Copy For Citation

Demirci N. S., AKSOY S., ÖZDEMİR N., Erdem G. U., Ozcelik M., Tanrikulu E., ...More

CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.3, pp.401-407, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 33 Issue: 3
Publication Date: 2017
Doi Number: 10.1080/03007995.2016.1257984
Journal Name: CURRENT MEDICAL RESEARCH AND OPINION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.401-407
Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Aim: Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) therapy has been shown to be a well tolerated and highly effective regimen for metastatic gastric carcinoma. Herein we investigated the effectiveness of the mDCF combination as the first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC).